

TRANSPLANTATION

CME Article

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

Kazuhiko Kakihana,^{1,*} Yuki Fujioka,^{2,3,*} Wataru Suda,^{4,5,*} Yuho Najima,¹ Go Kuwata,⁶ Satoshi Sasajima,⁷ Iyo Mimura,⁸ Hidetoshi Morita,⁸ Daisuke Sugiyama,² Hiroyoshi Nishikawa,² Masahira Hattori,^{4,9} Yutaro Hino,¹ Shuntaro Ikegawa,¹ Keita Yamamoto,¹ Takashi Toya,¹⁰ Noriko Doki,¹ Koichi Koizumi,⁶ Kenya Honda,^{5,7,11} and Kazuteru Ohashi¹

¹Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan; ²Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan; ³Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan; ⁴Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan; ⁵Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; ⁶Gastroenterology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan; ⁷Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan; ⁸Graduate School of Environmental and Life Science, Okayama University, Okayama, Japan; ⁹Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan; ¹⁰Department of Hematology and Oncology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan; and ¹¹Japan Agency for Medical Research and Development–Core Research for Evolutional Science and Technology, Tokyo, Japan

Key Points

- FMT was safely performed in SCT patients, with 3 complete responses and 1 partial response.
- Temporal microbiota dynamics seem linked to gut condition and effector regulatory T cells also increased during response to FMT.

Increasing evidence indicates that the gut microbiota is closely associated with acute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immunosuppressed status. We therefore conducted a pilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant ($n = 3$) or steroid-dependent gut aGVHD ($n = 1$) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD. This trial was registered at the University Hospital Medical Information Network (https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017575) as #UMIN000015115. (*Blood*. 2016;128(16):2083-2088)

Medscape Continuing Medical Education online

This activity has been planned and implemented through the joint providership of Medscape, LLC and the American Society of Hematology. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at <http://www.medscape.org/journal/blood>; and (4) view/print certificate. For CME questions, see page 2107.

Disclosures

Laurie Barclay, freelance writer and reviewer, Medscape, LLC, owns stock, stock options, or bonds from Pfizer. Associate Editor Robert Zeiser and the authors declare no competing financial interests.

Submitted 18 May 2016; accepted 18 July 2016. Prepublished online as *Blood* First Edition paper, 26 July 2016; DOI 10.1182/blood-2016-05-717652.

*K. Kakihana, Y.F., and W.S. contributed equally to this study.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2016 by The American Society of Hematology

Medscape Continuing Medical Education online

Learning Objectives

1. Determine the safety of fecal microbiota transplantation (FMT) for treating acute graft-versus-host disease (aGVHD) of the gut after stem cell transplantation (SCT).
2. Determine the efficacy of FMT for treating gut aGVHD after SCT.
3. Assess potential mechanisms underlying FMT as a potential treatment for gut aGVHD after SCT.

Release date: October 20, 2016; October 20, 2017

Introduction

Although allogeneic stem cell transplantation (allo-SCT) is a curative treatment of various hematological diseases, acute graft-versus-host disease (aGVHD) represents a major cause of morbidity and mortality. Glucocorticoids are used as the first-line therapy for aGVHD, but only about half of patients respond¹ and no second-line treatment has yet been established.

The gut microbiota and its metabolites have been reported to play pivotal roles in intestinal inflammation and the immune system.^{2,3} Also in allo-SCT, increasing evidence indicates that the gut microbiota is closely associated with aGVHD.⁴⁻¹⁰ Fecal microbiota transplantation (FMT) refers to infusion of a fecal suspension from a healthy donor into the gastrointestinal tract of a patient to restore a healthy microbiota and cure disease. Manipulation of the intestinal microbiota by FMT may influence the immune system and improve immune-mediated enteritis such as gut aGVHD. However, FMT carries a potential risk of infection by the infused microbiota for SCT recipients. We therefore conducted this pilot study to evaluate the safety of FMT for treating steroid-resistant or steroid-dependent gut aGVHD.

Study design

Four patients with gut aGVHD (steroid-resistant, n = 3; steroid-dependent, n = 1) underwent this pilot study (Table 1¹¹).

The patient's spouse or a relative who passed the screening for transmissible diseases could be a candidate for FMT donor. The maximum number of treatments was 2 and all adverse events (AEs) that first arose or progressed within 1 week after each infusion were evaluated in terms of the safety of FMT. Response to FMT was evaluated 28 days after the final FMT (cases 1-3) or at the time of maximum response (case 4).

Microbial analyses were performed using 16 ribosomal RNA gene sequencing. For immunological assays, peripheral mononuclear cells were isolated before and after FMT, and analyzed by flow cytometry (detailed information about the study protocol is provided in supplemental Methods, available on the *Blood* Web site).

Results and discussion

The underlying disease in all patients was acute myeloid leukemia (Table 1). Case 3 was diagnosed with late-onset aGVHD. The first FMT was performed at a median of 92 days after SCT (60-174 days). All patients received the first FMT while receiving methylprednisolone (mPSL) at ≥ 1 mg/kg and showed comorbid infectious complications at the start of FMT (Table 1).

Median feces volume was 126 g (34-307 g) and the final volume of the fecal suspension was 180 to 230 mL. Fecal suspensions were

administered over 4 to 8 minutes via a nasoduodenal tube. FMTs were performed at a median of 6 hours (2.75-9 hours) after feces collection (supplemental Table 1). All AEs that were obviously related to FMT were mild and transient (underlined in Table 1). Case 4 developed AEs such as hypoxia, paroxysmal atrial fibrillation (PAF), lower gastrointestinal bleeding, cholestatic liver damage, and transplant-associated thrombotic microangiopathy. In addition, case 4 also developed fever 2 days after the second FMT. The possibility of an association between FMT and these AEs could not be completely ruled out. Indeed, gastrointestinal bleeding and PAF may be induced by FMT-related complications such as mechanical mucosal damage by tube insertion, or mental discomfort. However, the patient presented with fresh blood in the stool, not tarry stool, and PAF occurred 4 days after the second FMT. Thus, it seemed more plausible that various underlying conditions, such as poor performance status, hypoalbuminemia (≤ 2 g/dL), severe cytopenias, use of various drugs, or Epstein-Barr virus reactivation, contributed to the development of these AEs. A febrile episode after the second FMT resolved within 1 day and no pathogens were detected. These results thus suggest that normal microbiota^{12,13} might be administered safely in SCT patients (for the detailed clinical course of each patient, please see supplemental Results and discussion).

With regard to response, FMT was effective in all patients, with complete response in 3 patients and partial response in 1 case, and improvement of gastrointestinal symptoms was observed within several days in the steroid-resistant cases. Moreover, the steroid dose was able to be successfully reduced by more than half (mean, 69% reduction) compared with that before FMT in cases 1 to 3 (supplemental Figure 1).

Clinical courses and temporal microbiota dynamics in each patient are shown in Figure 1A. Case 1 showed favorable recovery from gastrointestinal symptoms after FMT and the final microbiota composition was dominated by *Lactobacillus* and *Bacteroides* (Figure 1Ai). In case 2, improvement of gastrointestinal symptoms after the first FMT was transient and minimal, but gradually improved after the second FMT. *Streptococcus* decreased after FMT and this became more prominent after the second FMT. The final microbiota composition was dominated by *Bacteroides*, *Lactobacillus*, and *Bifidobacterium* (Figure 1Aii). In case 3, gastrointestinal symptoms remitted after reescalating mPSL and were not exacerbated. The microbiota after FMT mainly comprised *Bacteroides*, *Bifidobacterium*, and *Faecalibacterium*, and this composition was maintained during the study period (Figure 1Aiii). In case 4, gastrointestinal symptoms gradually improved after 2 courses of FMT, but eventually flared after rapid reduction of mPSL and tacrolimus for transplant-associated thrombotic microangiopathy (13 days after the second FMT). This patient's feces were eventually occupied by *Escherichia* at the time of recurrence of gut aGVHD (Figure 1Aiv). Temporal microbiota dynamics thus seemed to be linked to the gut condition of the patient. Beneficial bacteria such as *Bacteroides*,⁵ *Lactobacillus*,⁸ *Bifidobacterium*,

Table 1. Patient characteristics, AEs, and response

	Case 1	Case 2	Case 3	Case 4
Age, y/Sex	64/Female	44/Female	48/Male	42/Male
Diagnosis	AML	AML with 3q26.2 abn	MK-AML	AML-MRC
Indication for FMT	Resistant	Resistant	Dependent	Resistant
GVHD stage (overall)				
Gut	1	4	1	2*
Skin	0	0	0	0
Liver	0	3	3	1
GVHD grade (overall)	II	III	II	IV†
GVHD stage at start of FMT				
Gut	1	4	1	2*
Skin	0	0	0	0
Liver	0	0	0	1
GVHD grade at start of FMT	II	III	II	IV†
Initial treatment dose of steroid	2 mg/kg mPSL	2 mg/kg mPSL	>2 mg/kg mPSL	1-2 mg/kg mPSL
Dose of steroid at start of FMT	1 mg/kg mPSL	1 mg/kg mPSL	>2 mg/kg mPSL	2 mg/kg mPSL
Treatment of GVHD other than systemic steroid	FK, beclomethasone	FK, beclomethasone, octreotide, loperamide, fentanyl	FK, beclomethasone	FK, beclomethasone, octreotide
Infectious complications and treatment at start of FMT				
<i>Clostridium difficile</i> toxin	—	—	—	—
Comorbid infection	CMV antigenemia	IPA CMV retinitis	IPA	Sepsis (catheter infection) CMV enteritis
Antibiotics	ST, TAZ/PIPC	LVFX	CFPM + VCM	CFPM
Cessation of antibiotics	Yes (TAZ/PIPC)	Yes	Yes	No
Antifungals	MCFG	VRCZ	L-AmphB	MCFG
Antivirals	Foscarnet	Ganciclovir (intraocular) Foscarnet	Aciclovir	Foscarnet
AEs (grade)				
First FMT	<u>Abdominal pain (1)</u>	<u>Belch (1)</u> <u>Pharyngolaryngeal pain (1)</u> <u>Diarrhea (2)</u> Hypokalemia (L-AmphB induced) (2)	<u>Diarrhea (1)</u> Anemia (2–3)‡ Thrombocytopenia (3→4)‡	Hypoxia (2) Delirium (1) Lower GI hemorrhage (1) Hypothyroidism (1) γGTP↑ (1–2)
Second FMT	<u>Abdominal pain (1)</u> <u>Pharyngolaryngeal pain (1)</u> <u>Nausea (1)</u>	<u>Abdominal pain (1)</u> <u>Pharyngolaryngeal pain (1)</u> <u>Diarrhea (2)</u>	NA	<u>Abdominal pain (1)</u> Fever (1)‡ Blood bilirubin increased (1→3) γGTP↑ (2→3) PAF (1) TA-TMA (2)§
Response	Complete response	Complete response	Complete response	Partial response

All AEs that were obviously related to FMT (underlined) were mild and transient.

AML, acute myeloid leukemia; AML-MRC, AML with myelodysplasia-related changes; AML with 3q26.2 abn, AML with 3q26 abnormality; CFPM, cefepime; CMV, cytomegalovirus; FK, tacrolimus; GI, gastrointestinal; GTP, guanosine triphosphate; IPA, invasive pulmonary aspergillosis; L-AmphB, liposomal amphotericin B; LVFX, levofloxacin; MCFG, micafungin; MK-AML, AML with monosomal karyotype; NA, not applicable; ST, sulfamethoxazole/trimethoprim; TAZ/PIPC, tazobactam/piperacillin; TA-TMA, transplant-associated thrombotic microangiopathy; VCM, vancomycin; VRCZ, voriconazole.

*Downgraded one stage because of CMV enteritis.

†Graded as IV because of extremely poor performance status.

‡Recovered in 1 day.

§TA-TMA was graded using the common toxicity criteria proposed by Ho et al.¹¹

||Response of FMT was evaluated 28 days after last infusion (cases 1-3) or as maximum response before rituximab administration (case 4).

and *Faecalibacterium*¹⁴ were dominant in cases 1 to 3,¹⁵ whereas *Escherichia*, which has been strongly correlated with GVHD in a mouse model,⁹ was increased at the recurrence of aGVHD in case 4. The number of operational taxonomic units and diversity of the intestinal microbiota did not fully recover after FMT, even with apparent clinical response (supplemental Figure 2). These results indicate that full recovery of the microbiota might not be indispensable for response to FMT. Indeed, in most SCT patients, the operational taxonomic unit count was very low compared with that in healthy volunteers, even in patients without aGVHD (K. Kakihana and N.D., unpublished data). Although antibiotics had to be resumed in cases 1 and 2, these patients responded to FMT and did not show exacerbation

after restarting antibiotics (Figure 1A). Reduced activity against intestinal anaerobic bacteria of the antibiotics used might have contributed to conserve the response to FMT.¹⁶ Furthermore, FMT could be performed without exacerbating comorbid infections in any patients. FMT thus may not negatively affect immunity against infection. Regulatory T cells (Tregs) have been reported as a prognostic cellular biomarker for aGVHD^{17,18} and the number of peripheral effector Tregs (eTregs; Figure 1Bi),¹⁹ which have been reported as terminally differentiated and highly suppressive,²⁰ increased during responding to FMT. The eTreg/CD8⁺ T-cell ratio showed a similar trend in most cases (Figure 1Bii). Similar results were obtained for overall FoxP3⁺CD4⁺ T cells (supplemental Figure 3). Although




Figure 1.




Figure 1. Components of microbiota and immunological assay. (A) Temporal dynamics of the microbiota (at the genus level) and clinical course in each patient: (i) case 1, (ii) case 2, (iii) case 3, and (iv) case 4. *1: Data from the day after first FMT could not be obtained because of the lack of fecal sample. (B) (i) Subpopulation of Tregs. Tregs can be dissected into 3 subpopulations by expression levels of FoxP3, CD45RA. FoxP3^{hi}CD45RA⁺ cells (fraction 1), designated as naive Tregs, which differentiate into eTregs under antigenic stimulation; FoxP3^{lo}CD45RA⁻ cells (fraction 2), designated as eTregs, which are terminally differentiated and highly suppressive; and FoxP3^{lo}CD45RA⁻ non-Tregs (fraction 3), which do not possess suppressive activity, but secrete proinflammatory cytokines.²⁰ (ii) The absolute number of eTregs (red lines) and the eTreg/CD8⁺ T-cell ratio (green lines) in peripheral blood of each patient. CAZ, ceftazidime; CFPM, cefepime; FK, tacrolimus; Fr, fraction; LVFX, levofloxacin; MEPM, meropenem; PSL, prednisolone; ST, sulfamethoxazole/trimethoprim; TAZ/PIPC, tazobactam/piperacillin; TEIC, teicoplanin; VCM, vancomycin.

somewhat conflicting, our results indicate that FMT might shift the systemic allogeneic immune response to an anti-inflammatory state by changing the intestinal microbiota and might be effective against other forms of aGVHD. Indeed, the intestinal microbiota has been reported to be associated with the entire spectrum of aGVHD.^{4,5,10}

In summary, FMT was safely performed in SCT patients and offers promise as a potential treatment option for aGVHD. Further evaluation to confirm the safety and efficacy of FMT for aGVHD is warranted. Despite the very small number of patients, our results are highly suggestive for elucidating the associations between microbiota and human immunity.

Acknowledgments

The authors are very grateful to the patients and FMT donors who participated in this study. The authors thank Noritaka Sekiya for his professional advice regarding antibiotic use and donor screening.

This work was supported by Grants-in-Aid for Scientific Research (B) (no. 26290054) (H.N.) and for challenging Exploratory Research

(no. 16K15551) (H.N.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by The National Cancer Center Research and Development Fund (no. 28-A-7) (H.N.).

Authorship

Contribution: K. Kakhiana, Y.N., T.T., and K.O. designed the study; K. Kakhiana, K. Koizumi, G.K., Y.N., S.I., K.Y., and Y.H. performed FMT and collected samples; S.S., N.D., I.M., H.M., Y.F., D.S., H.N., W.S., M.H., K. Kakhiana, and K.H. carried out research and analyzed the data; and K. Kakhiana, Y.F., and W.S. wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: K. Kakhiana, 0000-0001-5062-5795.

Correspondence: Kazuhiko Kakhiana, Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan; e-mail: kakhiana@cick.jp.

References

- Deeg HJ. How I treat refractory acute GVHD. *Blood*. 2007;109(10):4119-4126.
- Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. *Nature*. 2013;500(7461):232-236.
- Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature*. 2013;504(7480):451-455.
- Jenq RR, Taur Y, Devlin SM, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. *Biol Blood Marrow Transplant*. 2015;21(8):1373-1383.
- Biagi E, Zama D, Nastasi C, et al. Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT. *Bone Marrow Transplant*. 2015;50(7):992-998.
- Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. *Blood*. 2014;124(7):1174-1182.
- Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. *Biol Blood Marrow Transplant*. 2014; 20(5):640-645.

8. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. *J Exp Med*. 2012;209(5):903-911.
9. Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α -defensins. *Blood*. 2012;120(1):223-231.
10. Weber D, Oefner PJ, Hiergeist A, et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. *Blood*. 2015;126(14):1723-1728.
11. Ho VT, Cutler C, Carter S, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2005;11(8):571-575.
12. de Castro CG Jr, Ganc AJ, Ganc RL, Petrolli MS, Hamerschlack N. Fecal microbiota transplant after hematopoietic SCT: report of a successful case. *Bone Marrow Transplant*. 2015;50(1):145.
13. Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for *Clostridium difficile* infection: focus on immunocompromised patients. *J Infect Chemother*. 2015;21(4):230-237.
14. Sokol H, Pigneur B, Watterlot L, et al. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci USA*. 2008;105(43):16731-16736.
15. Shahinas D, Silverman M, Sittler T, et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. *MBio*. 2012;3(5):e00338-12.
16. Shono Y, Docampo MD, Smith OM, et al. Treatment with antibiotics containing activity against obligate anaerobes worsens GVHD survival in mice and humans after allogeneic BMT. *Biol Blood Marrow Transplant*. 2015;21(2):S27-S28.
17. Magenau JM, Qin X, Tawara I, et al. Frequency of CD4⁺CD25^{hi}FOXP3⁺ regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. *Biol Blood Marrow Transplant*. 2010;16(7):907-914.
18. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. *Blood*. 2004;104(7):2187-2193.
19. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3⁺CD4⁺ regulatory T cells, evoking antitumor immune responses in humans. *Proc Natl Acad Sci USA*. 2013;110(44):17945-17950.
20. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4⁺ T cells expressing the FoxP3 transcription factor. *Immunity*. 2009;30(6):899-911.